Generex Biotechnology Corporation  

(Public, OTCMKTS:GNBT)   Watch this stock  
Find more results for Brian McGee�
+0.0008 (4.65%)
Feb 27 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.02 - 0.02
52 week 0.01 - 0.05
Open 0.02
Vol / Avg. 885,107.00/1.33M
Mkt cap 14.22M
P/E     -
Div/yield     -
EPS 0.00
Shares 789.85M
Beta 1.20
Inst. own 0%

Key stats and ratios

Q4 (Oct '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets 4.04% -0.03%
Return on average equity - -
Employees 8 -
CDP Score - -


33 Harbour Sq Suite 202
+1-416-3642551 (Phone)

Website links


Generex Biotechnology Corporation is a Canada-based engaged primarily in the research and development of drug delivery systems and technologies. The Company�s primary focus is on its technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. Through its wholly owned subsidiary, Antigen, it has expanded its focus to include immunomedicines incorporating vaccine formulations. The Company has identified several molecule drugs as possible candidates for development, including estrogen, heparin, monoclonal antibodies, human growth hormone and fertility hormones, but has focused its development efforts primarily on one pharmaceutical product, Generex Oral-lyn an insulin formulation administered as a fine spray into the oral cavity using its hand-held aerosol spray applicator known as RapidMist.

Officers and directors

John P. Barratt Independent Chairman of the Board
Age: 68
Mark A. Fletcher Esq President, Chief Executive Officer, General Counsel, Director
Age: 47
Stephen Fellows Chief Financial Officer
Age: 47
David Brusegard Ph.D. Chief Operating Officer, Secretary
Age: 69
Eric von Hofe PhD Director
Age: 58
James H. Anderson Jr,MD Independent Director
Age: 66
Brian T. McGee Independent Director
Age: 52